drugset / Trial / NCT05868395
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Polatuzumab, bendamustine and rituximab in patients with relapsed/ refractory mantle cell lymphoma
Timeline
- Start
- 2024-01-02
- Primary completion
- 2027-05-24
- Completion
- 2027-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 90 mg/m2 | Intravenous |
| Subject | Polatuzumab Vedotin | Other / unclassified | 1.8 mg/kg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |